HK-listed Kintor Pharmaceutical jumps on COVID-19 deal with Shanghai Fosun

Kintor Pharmaceutical

15/07/2021 07:52

** Shares of Chinese biotech firm Kintor Pharmaceutical Ltd
 9939.HK  rise 8.4% to HK$62.80, the highest since July 2
    ** Stock set for the best day since June 28 
    ** Co says its subsidiary entered into a licensing agreement
with a unit of Shanghai Fosun Pharmaceutical (Group) Co Ltd
 600196.SS  on commercialisation of proxalutamide for the
treatment of COVID-19 indication in India and 28 African
countries  urn:newsml:reuters.com:*:nFWN2OQ1C3
    ** Says parties agreed to collaborate on emergency use
authorization applications, promotion, and sales of
proxalutamide for the treatment of COVID-19 indication and Fosun
Pharma will be granted exclusive rights of commercialisation of
proxalutamide in the regions
    ** Hong Kong shares of Shanghai Fosun  2196.HK  rise 5.6%
and Shanghai stock  600196.SS  jumps 6.6%
    ** The Hong Kong Hang Seng Commerce & Industry Index  .HSNC 
gains 0.7%, and the healthcare index  .HSCIH  slides 0.1%
    ** The Hang Seng China Enterprises Index  .HSCE  rises 1.3%,
and the benchmark index  .HSI  climbs 1%
    ** As of last close, Kintor shares had soared 454% this year

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))